Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
ERS Genomics and Cellular Engineering Technologies collaborating
/in News/by Thomas GabrielczykERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.
Visus Therapeutics cashes in 20m from LSP
/in News/by Thomas GabrielczykVisus Therapeutics has baged a 20m stock financing to advance development of Brimochol for presbyopia
British drug developer Mission Therapeutics plc earns $20m milestone
/in News/by Thomas GabrielczykBritish drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.
Spectricity raises 14m in Series B round
/in News/by Thomas GabrielczykBelgian semiconductor specialist Spectricity BV has baged 14m to speed up the development of mobile hyperspectral sensors for medical applications.
Abcam to acquire BioVision for $340m
/in News/by Thomas GabrielczykLife sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.
Byondis and Glycotope merge platforms to target carbohydrates
/in News/by Thomas GabrielczykCancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement.
Artios Pharma Ltd raises US-$153m Series C financing
/in News/by Thomas GabrielczykCancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline.
AXA IM Alts raises 1.9bn European Life Sciences Fund
/in News/by Thomas GabrielczykAXA IM Alts has raised 1.9bn of equity to accelerate investments into the Life Sciences sector.
Synaffix inks $246m deal with ProfoundBio
/in News/by Thomas GabrielczykSynaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal